What Is Methylmalonic Acidemia Symptoms Causes Treatment?

Methylmalonic acidemia is a rare inherited metabolic disorder in which the body cannot properly break down certain proteins and fats. This failure causes a toxic buildup of methylmalonic acid in the blood and tissues, which can lead to severe illness, organ damage, and neurological problems. The condition typically appears in infancy, though milder forms can emerge later in childhood or adulthood. Early diagnosis and careful dietary management are essential for reducing the risk of life-threatening complications.

What Is Methylmalonic Acidemia?

Methylmalonic acidemia (MMA) is part of a group of conditions called organic acidemias. In a healthy body, enzymes convert certain amino acids and odd-chain fatty acids into energy. In people with MMA, one of these enzymes is missing or does not work correctly. The most common defect involves the enzyme methylmalonyl-CoA mutase, or its cofactor, vitamin B12.

When this enzyme fails, the body cannot process several key amino acids, including isoleucine, valine, methionine, and threonine. Instead of being used for energy, these substances are broken down into methylmalonic acid and other toxic byproducts. These acids accumulate in the blood, urine, and organs, creating a metabolic crisis that can damage the brain, liver, and kidneys.

MMA is not one single disease. It is a group of related disorders with different genetic causes and varying degrees of severity. Some forms respond to high doses of vitamin B12. Others do not. Understanding which type a person has matters for treatment planning.

What Causes Methylmalonic Acidemia?

MMA is caused by mutations in genes that provide instructions for making enzymes involved in protein metabolism. The two most commonly affected genes are MMUT and MMACHC, though several other genes can also cause the condition.

The MMUT gene provides instructions for making methylmalonyl-CoA mutase, the enzyme that converts methylmalonyl-CoA to succinyl-CoA. When this enzyme is defective, the body cannot complete this critical metabolic step. Mutations in this gene cause what doctors call mut-type MMA, which is the most common and often the most severe form.

Other gene mutations affect the body’s ability to use vitamin B12, which is required for the mutase enzyme to function. These are called cblA, cblB, and cblC types. The cblC form is particularly complex because it also causes problems with homocysteine metabolism, leading to additional symptoms beyond those of classic MMA.

MMA is inherited in an autosomal recessive pattern. This means a child must inherit a defective copy of the gene from both parents to develop the condition. Parents who each carry one copy of the mutation typically show no symptoms themselves.

What Are the Symptoms of Methylmalonic Acidemia?

Symptoms usually appear in the first weeks or months of life, though the timing varies by genetic type and severity. The earliest signs often include poor feeding, vomiting, lethargy, and failure to gain weight. These symptoms can escalate quickly into a metabolic crisis, a medical emergency where acidic compounds overwhelm the blood.

During a metabolic crisis, a baby may develop rapid breathing, dehydration, low body temperature, and seizures. Without urgent treatment, the crisis can lead to coma or death. These episodes are often triggered by illness, infection, surgery, or fasting, which increase the body’s protein breakdown.

Beyond acute crises, children with MMA often experience long-term health problems. These may include developmental delay, intellectual disability, and growth problems. Some children develop movement disorders, weakness, or vision loss due to damage to the basal ganglia, a brain region that controls movement.

Kidney disease is another serious long-term complication. Many people with MMA gradually lose kidney function over time, and some eventually require dialysis or a kidney transplant. Pancreatitis, an inflammation of the pancreas, also occurs more frequently in people with MMA than in the general population.

Some individuals with milder forms of MMA may not show symptoms until adolescence or adulthood. In these cases, symptoms might be triggered by a serious infection, a prolonged fast, or high protein intake. Adult-onset symptoms can include confusion, weakness, or sudden metabolic decompensation.

How Is Methylmalonic Acidemia Diagnosed?

Most babies in the United States and many other countries are screened for MMA at birth through newborn screening programs. A blood spot test measures levels of specific compounds, including propionylcarnitine, which is elevated in MMA. When the screening result is abnormal, confirmatory testing is needed.

Confirmatory tests include measuring organic acids in urine, amino acids in blood, and specific acylcarnitine profiles. Elevated methylmalonic acid in the urine and blood is the hallmark finding. Genetic testing can identify the specific gene mutation and help determine the exact type of MMA.

For families who already know they carry MMA mutations, prenatal testing is available. This can involve chorionic villus sampling or amniocentesis, procedures that carry small risks but can provide a diagnosis before birth.

What Are the Treatment Options for Methylmalonic Acidemia?

Treatment for MMA focuses on three main goals: preventing metabolic crises, managing daily metabolism, and treating complications as they arise. There is no cure for the underlying enzyme defect, but careful management can significantly improve outcomes.

Dietary management is the cornerstone of daily treatment. People with MMA follow a low-protein diet that limits the specific amino acids the body cannot process. A special medical formula provides essential nutrients without the problematic amino acids. A metabolic dietitian works closely with families to balance protein restriction against the body’s needs for growth and development.

Some forms of MMA respond to high-dose vitamin B12 supplementation. This treatment works best for certain cbl types where the enzyme is present but not functioning optimally. A trial of vitamin B12 is typically conducted at diagnosis to determine whether the person is B12-responsive. People who respond may need less strict protein restriction.

Other daily medications include L-carnitine, which helps remove toxic acids from the body, and antibiotics such as metronidazole, which reduce the production of propionic acid by bacteria in the gut.

During a metabolic crisis, treatment requires hospitalization. Intravenous fluids, glucose, and bicarbonate are given to correct dehydration and acidosis. Medications to remove ammonia from the blood may be needed if ammonia levels are dangerously high. Protein intake is stopped temporarily, and calories are provided through glucose and lipids.

For people with severe, difficult-to-control MMA, liver transplantation or combined liver-kidney transplantation may be considered. A liver transplant provides a new source of the missing enzyme, which can dramatically improve metabolic control. However, transplantation carries significant surgical risks and requires lifelong immunosuppression. It is generally reserved for people with frequent crises or severe complications that do not respond to medical management.

No clinical guidelines currently exist for treating adults with mild, late-onset MMA. Management in these cases is individualized based on symptom severity and metabolic status.

What Is the Long-Term Outlook for People with Methylmalonic Acidemia?

The outlook varies widely depending on the genetic type, age at diagnosis, and quality of metabolic control. Children who are diagnosed early and maintain good metabolic control often do well, though most will face ongoing health challenges.

Even with optimal treatment, many people with MMA experience some degree of developmental delay or learning difficulty. The risk of kidney disease increases with age, and regular monitoring of kidney function is essential. Neurological complications, including movement disorders and vision problems, can develop despite good metabolic control.

Research published in the Journal of Inherited Metabolic Disease has shown that early diagnosis through newborn screening has improved survival rates for children with MMA. However, long-term outcomes are still highly variable. Some individuals live relatively normal lives with careful management, while others experience frequent hospitalizations and significant disability.

Because MMA is a chronic condition, lifelong follow-up with a metabolic specialist is necessary. Regular monitoring includes blood tests, urine tests, growth assessments, kidney function checks, and developmental evaluations.

Can Methylmalonic Acidemia Be Prevented?

There is no way to prevent MMA in a child who has inherited the genetic mutations. However, for families with a known history of MMA, genetic counseling can help explain the risks and options. Carrier testing can identify adults who carry one copy of a mutation, and prenatal testing can determine whether a fetus is affected.

In some cases, preimplantation genetic diagnosis can be used during in vitro fertilization. This technique allows embryos to be tested for MMA mutations before implantation, reducing the chance of having an affected child.

For babies already diagnosed with MMA, early treatment is the best prevention against severe complications. Prompt dietary intervention and careful monitoring from the first days of life can reduce the frequency and severity of metabolic crises.